No Data
No Data
Daan Gene (002030.SZ) announced first-quarter results, changing profit to loss of 363 million yuan
Daan Gene (002030.SZ) released its report for the first quarter of 2024. The company's revenue was 1.98...
Daan Gene (002030.SZ): Net profit for 2023 fell 98.07% to 105 million yuan, and plans to distribute 10 0.15 yuan
On March 29, Ge Longhui (002030.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,181 million yuan, a year-on-year decrease of 90.20%; net profit attributable to shareholders of listed companies was 105 million yuan, a year-on-year decrease of 98.07%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - 364 million yuan; basic income per share was 0.0746 yuan; it plans to distribute a cash dividend of 0.15 yuan (tax included) for every 10 shares to all shareholders.
Daan Gene (002030.SZ): The main products are PCR diagnostic reagents and related consumables, instruments, etc.
Gelonghui March 28 | Daan Gene (002030.SZ) said on the investor interactive platform that the company's main products are PCR diagnostic reagents and related consumables, instruments, etc. Yunkang Group, the company's shareholding company, will continue to increase investment in R&D, focusing on the fields of precision medicine and intelligent testing to meet increasingly refined and personalized market needs. AI-assisted diagnosis is a trend in the development of inspection and diagnosis technology. Effective use of this technology will improve the accuracy and efficiency of diagnosis and reduce operating costs. In the field of clinical testing, Yunkang Group will introduce and develop AI technology applications in the process of interpreting genetic sequencing reports. In the field of pathology
Express News | Daan Gene: Human SLCO1B1 genotyping kit obtains medical device registration certificate
Daan Gene (002030.SZ) obtained a medical device registration certificate
Daan Gene (002030.SZ) announced that the company obtained a medical device registration certificate issued by the State Drug Administration...
Daan Gene (002030.SZ): Daan Technology received a cash dividend of 6.1515 million yuan
Gelonghui, January 31, 丨 Daan Gene (002030.SZ) announced that Guangzhou Daan Gene Technology Co., Ltd. (“Daan Technology”), a wholly-owned subsidiary of the company, recently received a cash dividend of 6.151,500 yuan from its shareholding company Hangzhou Anyu Biotechnology Co., Ltd. (“Anyu Biotech”).
No Data